HRT Financial’s Acrivon Therapeutics ACRV Stock Holding History

HRT Financial’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-145,895	Closed	-$173K	–	2778
2025 Q2	$173K	Buy	+145,895	New	+$200K	﹤0.01%	2105

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial's ACRV Position: Q3 2025 in Review

HRT Financial sold out of Acrivon Therapeutics (ACRV) in Q3 2025, closing a stake of 145,895 shares — an estimated $173K sold.

HRT Financial first reported a position in ACRV in Q2 2025 and held it in 1 quarter. The position peaked at $173K in Q2 2025. 48 funds tracked by Wall St. Rank hold ACRV as of Q3 2025.

HRT Financial reported no remaining Acrivon Therapeutics position as of Q3 2025 after selling out during the quarter.
HRT Financial sold 145,895 Acrivon Therapeutics shares in Q3 2025, an estimated $173K.
HRT Financial first reported a position in Acrivon Therapeutics in Q2 2025 and held it in 1 quarter.
HRT Financial's Acrivon Therapeutics position peaked at $173K in Q2 2025.
48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.